Liver Cancer Therapeutics Global Market Report 2025
상품코드:1760597
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
간암 치료 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상되며, 2029년까지 16.8%의 CAGR로 55억 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 전 세계 간암 발병률 증가, B형 및 C형 간염의 높은 유병률, 알코올 관련 간 질환의 증가, 비알코올성 지방간 질환의 증가, 면역 치료 접근법의 채택 확대 등에 기인합니다. 예측 기간의 주요 동향으로는 신약개발에 AI와 ML의 통합, 임상시험에서 빅데이터와 실제 증거의 활용, 영상기술의 발전, 최소침습적 진단 도구의 채택, 종양학 후속 치료에서 원격의료와 디지털 건강의 활용 등이 있습니다.
B형 간염 감염의 증가는 간암 치료 시장의 성장을 촉진할 것으로 예상됩니다. B형 간염은 주로 간을 침범하여 간암과 같은 급성 및 만성 건강 문제를 유발할 수 있는 B형 간염 바이러스(HBV)에 의해 발생하는 바이러스성 질환입니다. B형 간염 감염의 증가는 오염된 주사바늘과 주사기 공유를 통해 바이러스를 전파하는 주사제 사용의 증가로 인해 부분적으로 촉진되고 있으며, B형 간염에 만성적으로 감염되면 간 염증과 세포 손상이 진행되어 시간이 지남에 따라 악성 간 질환의 위험이 크게 증가하므로 간암 치료는 B형 간염 감염 관리에 필수적입니다. 예를 들어, 세계보건기구(WHO)가 2024년 4월 발표한 보고서에 따르면, 2022년에는 전 세계적으로 2억 5,400만 명 이상이 B형 간염에 감염되어 있으며, 120만 명이 새로 B형 간염에 감염된 것으로 보고되고 있습니다. 또한, B형 간염은 전 세계 바이러스성 간염 관련 사망자 130만 명의 83%를 차지했습니다. 이에 따라 B형 간염 감염의 증가는 간암 치료 시장의 성장을 가속화할 것으로 보입니다.
혁신적인 치료법, 특히 면역치료의 발전을 통해 간암 치료 시장의 성장을 주도하고 있습니다. 간암 치료제 시장의 주요 기업들은 장기간 효과가 지속되는 처방 면역치료제와 같은 최첨단 치료법 개발에 주력하고 있습니다. 이러한 의약품은 면역 반응을 표적으로 삼고 이를 조절하여 암과 만성 감염을 포함한 특정 질병을 퇴치하기 위해 신체의 면역 체계를 강화하거나 억제함으로써 작용합니다. 예를 들어, 2025년 4월 미국 바이오 제약사 브리스톨 마이어스 스퀴브(Bristol-Myers Squibb)는 미국 식품의약국(FDA)으로부터 난치성 또는 전이성 원발성 간세포암(HCC) 성인 환자를 대상으로 옵디보(니볼루맙)와 여보이(이필리무맙)를 1차 치료제로 승인받았습니다. 이필리맙)을 1차 치료제로 승인했다고 발표했습니다. 이번 승인은 전 세계적으로 진행된 3상 무작위배정 오픈라벨 임상 3상 CheckMate-9DW의 결과에 근거한 것으로, 전신 치료 경험이 없는 전이성 또는 절제 불가능한 간세포암 환자를 대상으로 티로신 키나아제 억제제(렌바티닙 또는 소라페닙)와 옵디보+여보이 병용요법군으로 무작위 배정했을 때, 전체 생존기간(OS)과 전체 반응률(ORR)이 비교군 대비 통계적으로 유의하게 개선된 것으로 나타났습니다. 이 병용요법은 이 설정에서 우수한 결과를 보여 FDA의 승인을 받은 유일한 치료법입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 거시경제 시나리오 : 금리·인플레이션·지정학·무역 전쟁·관세·코로나와 회복이 시장에 미치는 영향을 포함한다
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 간암 치료 시장 : PESTEL 분석(정치·사회·기술·환경·법적 요인, 촉진요인, 억제요인)
최종 이용 산업 분석
세계의 간암 치료 시장 : 성장률 분석
세계의 간암 치료 시장 규모·성장률 : 실적치, 2019-2024년
세계의 간암 치료 시장 규모·성장률 : 예측치, 2024-2029년, 2034년
세계의 간암 치료 시장 : 총유효과 시장(TAM)
제6장 시장 세분화
세계의 간암 치료 시장 : 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
간세포암
담관암
간아종
기타 종류
세계의 간암 치료 시장 : 치료법 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
표적요법
면역요법
화학요법
방사선 치료
기타 치료법
세계의 간암 치료 시장 : 유통 채널별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
병원 약국
소매 약국
온라인 약국
세계의 간암 치료 시장 : 최종사용자별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
소아
성인
세계의 간암 치료 시장 : 간세포암 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
국소성 간세포암
진행 간세포암
재발성 간세포암
세계의 간암 치료 시장 : 담관암 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
간내 담관암
간외 담관암
문맥 주위 담관암
세계의 간암 치료 시장 : 간아종 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
표준 리스크 간아종
고위험 간아종
전이성 간아종
세계의 간암 치료 시장 : 기타 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
섬유층 암
간 혈관육종
혈관육종
제7장 지역별·국가별 분석
세계의 간암 치료 시장 : 지역별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
세계의 간암 치료 시장 : 국가별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
간암 치료 시장 : 경쟁 구도
간암 치료 시장 : 기업 개요
Pfizer Inc.(개요, 제품 및 서비스, 전략, 재무 분석)
F. Hoffmann-La Roche Ltd.(개요, 제품 및 서비스, 전략, 재무 분석)
Merck & Co. Inc.(개요, 제품 및 서비스, 전략, 재무 분석)
Novartis AG(개요, 제품 및 서비스, 전략, 재무 분석)
Bayer AG(개요, 제품 및 서비스, 전략, 재무 분석)
제31장 기타 주요 기업과 혁신적 기업
Sanofi SA
Bristol-Myers Squibb
AstraZeneca PLC
Amgen Inc.
Eli Lilly and Company
Gilead Sciences Inc.
Regeneron Pharmaceuticals Inc.
Eisai Co. Ltd.
Ipsen
Exelixis Inc.
BeiGene Ltd.
Hutchmed
Celgene Corporation
Zymeworks Inc.
Can-Fite BioPharma
제32장 세계 시장 : 경쟁 벤치마킹·대시보드
제33장 주요 기업 인수합병(M&A)
제34장 최근의 시장 동향
제35장 시장 잠재력 높은 나라·부문과 전략
간암 치료 시장 : 최신 기회를 제공하는 국가(2029년)
간암 치료 시장 : 최신 기회를 제공하는 부문(2029년)
간암 치료 시장 : 성장 전략(2029년)
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Liver cancer therapeutics involve a range of treatments designed to manage abnormal cell growth in the liver, a vital organ responsible for essential metabolic and detoxification functions. These therapies aim to target, control, or eradicate harmful cellular activity while preserving as much healthy tissue as possible.
The main types of liver cancer therapeutics include treatments for hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and other liver cancers. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, originating in the liver's hepatocytes (the primary liver cells). It is a leading cause of cancer-related deaths worldwide, especially in regions with high rates of chronic liver diseases including hepatitis B, hepatitis C, alcohol-related liver disease, and cirrhosis (liver scarring). Treatments for HCC include targeted therapy, immunotherapy, chemotherapy, radiation therapy, and others. These therapies are available through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a wide range of patients, including both adults and children.
The liver cancer therapeutics market research report is one of a series of new reports from The Business Research Company that provides liver cancer therapeutics market statistics, including liver cancer therapeutics industry global market size, regional shares, competitors with a liver cancer therapeutics market share, detailed liver cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer therapeutics industry. This liver cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The liver cancer therapeutics market size has grown rapidly in recent years. It will grow from $2.52 billion in 2024 to $2.95 billion in 2025 at a compound annual growth rate (CAGR) of 17.1%. The growth observed in the historical period can be attributed to higher funding from government and non-profit organizations, rising global healthcare spending, expanding health insurance coverage in developing nations, an aging global population, and the increasing prevalence of obesity and diabetes.
The liver cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $5.50 billion in 2029 at a compound annual growth rate (CAGR) of 16.8%. The growth projected for the forecast period can be attributed to the increasing global incidence of liver cancer, the high prevalence of hepatitis B and C infections, the rise in alcohol-related liver disease, a growing number of non-alcoholic fatty liver disease cases, and the expanding adoption of immunotherapy approaches. Key trends in the forecast period include the integration of AI and ML in drug discovery, the use of big data and real-world evidence in clinical trials, advancements in imaging technologies, the adoption of minimally invasive diagnostic tools, and the use of telemedicine and digital health in oncology follow-up care.
The increasing incidence of hepatitis B infections is expected to drive the growth of the liver cancer therapeutics market. Hepatitis B is a viral disease caused by the hepatitis B virus (HBV), primarily affecting the liver and potentially leading to both acute and chronic health issues, including liver cancer. The rise in hepatitis B infections is partially fueled by the growing use of injection drugs, which spread the virus through the sharing of contaminated needles and syringes. Liver cancer therapeutics are essential for managing hepatitis B infections, as chronic infection can result in ongoing liver inflammation and cellular damage, significantly raising the risk of malignant liver conditions over time. For example, a report published by the World Health Organization (WHO) in April 2024 indicated that in 2022, over 254 million people globally were living with hepatitis B, with 1.2 million new cases recorded. Hepatitis B was also responsible for 83% of the 1.3 million viral hepatitis-related deaths worldwide. Consequently, the rising incidence of hepatitis B infections will accelerate the growth of the liver cancer therapeutics market.
Innovative therapies are driving growth in the liver cancer treatment market, particularly through advancements in immunotherapy. Leading companies in the liver cancer therapeutics market are focusing on developing cutting-edge treatments, such as prescription immunotherapy drugs, to offer long-lasting effects. These medications work by enhancing or suppressing the body's immune system to fight specific diseases, including cancer or chronic infections, by targeting and modulating immune responses. For example, in April 2025, Bristol Myers Squibb, a U.S.-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Opdivo (nivolumab) and Yervoy (ipilimumab) for adult patients with hepatocellular carcinoma (HCC), the most common type of primary liver cancer, either incurable or metastatic, as a first-line treatment. The approval was based on the results of the global Phase 3 randomized, open-label CheckMate-9DW trial, which showed that patients with metastatic or incurable HCC who had not previously received systemic therapy and were randomized to receive Opdivo plus Yervoy along with a tyrosine kinase inhibitor (lenvatinib or sorafenib) experienced statistically significant improvements in overall survival (OS) and overall response rate (ORR) compared to the comparator group. This combination therapy was the only one supporting an FDA approval with superior results in this setting.
In September 2023, Coherus BioSciences Inc., a U.S.-based biopharmaceutical company, acquired Surface Oncology Inc. for an undisclosed amount. This acquisition strengthens Coherus' immuno-oncology pipeline, which now includes four distinct clinical-stage assets toripalimab (anti-PD-1), casdozokitug (IL-27-targeted), CHS-114 (CCR8-targeted), and CHS-006 (TIGIT-targeted). The focus of development will be on achieving breakthrough survival benefits for cancer patients, aiming to surpass the efficacy of current chemotherapy combined with checkpoint inhibitor regimens. Surface Oncology Inc. is a US-based company, focusing on developing therapeutics for liver cancer.
Major players in the liver cancer therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca PLC, Amgen Inc., Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Ipsen, Exelixis Inc., BeiGene Ltd., Hutchmed, Celgene Corporation, Zymeworks Inc., Can-Fite BioPharma, and Onyx Pharmaceuticals Inc.
North America was the largest region in the liver cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in liver cancer therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the liver cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The liver cancer therapeutics market consists of revenues earned by entities by providing services such as diagnostics and screening, personalized treatment planning, minimally invasive procedures, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer therapeutics market also includes sales of drug delivery systems, diagnostic kits, biologics and supportive medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Liver Cancer Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on liver cancer therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for liver cancer therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liver cancer therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Hepatocellular Carcinoma; Cholangio Carcinoma; Hepatoblastoma; Other Types
2) By Therapy Type: Targeted Therapy; Immunotherapy; Chemotherapy; Radiation Therapy; Other Therapy Types
3) By Distribution Channel Type: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Liver Cancer Therapeutics Market Characteristics
3. Liver Cancer Therapeutics Market Trends And Strategies
4. Liver Cancer Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Liver Cancer Therapeutics Growth Analysis And Strategic Analysis Framework
5.1. Global Liver Cancer Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Liver Cancer Therapeutics Market Growth Rate Analysis
5.4. Global Liver Cancer Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Liver Cancer Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Liver Cancer Therapeutics Total Addressable Market (TAM)
6. Liver Cancer Therapeutics Market Segmentation
6.1. Global Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types
6.2. Global Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Therapy
Immunotherapy
Chemotherapy
Radiation Therapy
Other Therapy Types
6.3. Global Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.4. Global Liver Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatrics
Adults
6.5. Global Liver Cancer Therapeutics Market, Sub-Segmentation Of Hepatocellular Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Localized Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
Recurrent Hepatocellular Carcinoma
6.6. Global Liver Cancer Therapeutics Market, Sub-Segmentation Of Cholangiocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intrahepatic Cholangiocarcinoma
Extrahepatic Cholangiocarcinoma
Perihilar Cholangiocarcinoma
6.7. Global Liver Cancer Therapeutics Market, Sub-Segmentation Of Hepatoblastoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Standard-Risk Hepatoblastoma
High-Risk Hepatoblastoma
Metastatic Hepatoblastoma
6.8. Global Liver Cancer Therapeutics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fibrolamellar Carcinoma
Angiosarcoma Of The Liver
Hemangiosarcoma
7. Liver Cancer Therapeutics Market Regional And Country Analysis
7.1. Global Liver Cancer Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Liver Cancer Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Liver Cancer Therapeutics Market
8.1. Asia-Pacific Liver Cancer Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Liver Cancer Therapeutics Market
9.1. China Liver Cancer Therapeutics Market Overview
9.2. China Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Liver Cancer Therapeutics Market
10.1. India Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Liver Cancer Therapeutics Market
11.1. Japan Liver Cancer Therapeutics Market Overview
11.2. Japan Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Liver Cancer Therapeutics Market
12.1. Australia Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Liver Cancer Therapeutics Market
13.1. Indonesia Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Liver Cancer Therapeutics Market
14.1. South Korea Liver Cancer Therapeutics Market Overview
14.2. South Korea Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Liver Cancer Therapeutics Market
15.1. Western Europe Liver Cancer Therapeutics Market Overview
15.2. Western Europe Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Liver Cancer Therapeutics Market
16.1. UK Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Liver Cancer Therapeutics Market
17.1. Germany Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Liver Cancer Therapeutics Market
18.1. France Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Liver Cancer Therapeutics Market
19.1. Italy Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Liver Cancer Therapeutics Market
20.1. Spain Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Liver Cancer Therapeutics Market
21.1. Eastern Europe Liver Cancer Therapeutics Market Overview
21.2. Eastern Europe Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Liver Cancer Therapeutics Market
22.1. Russia Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Liver Cancer Therapeutics Market
23.1. North America Liver Cancer Therapeutics Market Overview
23.2. North America Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Liver Cancer Therapeutics Market
24.1. USA Liver Cancer Therapeutics Market Overview
24.2. USA Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Liver Cancer Therapeutics Market
25.1. Canada Liver Cancer Therapeutics Market Overview
25.2. Canada Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Liver Cancer Therapeutics Market
26.1. South America Liver Cancer Therapeutics Market Overview
26.2. South America Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Liver Cancer Therapeutics Market
27.1. Brazil Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Liver Cancer Therapeutics Market
28.1. Middle East Liver Cancer Therapeutics Market Overview
28.2. Middle East Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Liver Cancer Therapeutics Market
29.1. Africa Liver Cancer Therapeutics Market Overview
29.2. Africa Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Liver Cancer Therapeutics Market Competitive Landscape And Company Profiles
30.1. Liver Cancer Therapeutics Market Competitive Landscape
30.2. Liver Cancer Therapeutics Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
31. Liver Cancer Therapeutics Market Other Major And Innovative Companies
31.1. Sanofi SA
31.2. Bristol-Myers Squibb
31.3. AstraZeneca PLC
31.4. Amgen Inc.
31.5. Eli Lilly and Company
31.6. Gilead Sciences Inc.
31.7. Regeneron Pharmaceuticals Inc.
31.8. Eisai Co. Ltd.
31.9. Ipsen
31.10. Exelixis Inc.
31.11. BeiGene Ltd.
31.12. Hutchmed
31.13. Celgene Corporation
31.14. Zymeworks Inc.
31.15. Can-Fite BioPharma
32. Global Liver Cancer Therapeutics Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Liver Cancer Therapeutics Market
34. Recent Developments In The Liver Cancer Therapeutics Market
35. Liver Cancer Therapeutics Market High Potential Countries, Segments and Strategies
35.1 Liver Cancer Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Liver Cancer Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Liver Cancer Therapeutics Market In 2029 - Growth Strategies
